BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36765664)

  • 1. Chemotherapeutic Activity of Pitavastatin in Vincristine Resistant B-Cell Acute Lymphoblastic Leukemia.
    Piktel D; Moore JC; Nesbit S; Sprowls SA; Craig MD; Rellick SL; Nair RR; Meadows E; Hollander JM; Geldenhuys WJ; Martin KH; Gibson LF
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pitavastatin Is Anti-Leukemic in a Bone Marrow Microenvironment Model of B-Lineage Acute Lymphoblastic Leukemia.
    Piktel D; Nair RR; Rellick SL; Geldenhuys WJ; Martin KH; Craig MD; Gibson LF
    Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The MitoNEET Ligand NL-1 Mediates Antileukemic Activity in Drug-Resistant B-Cell Acute Lymphoblastic Leukemia.
    Geldenhuys WJ; Nair RR; Piktel D; Martin KH; Gibson LF
    J Pharmacol Exp Ther; 2019 Jul; 370(1):25-34. PubMed ID: 31010844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mechanism of miR-155 Promoting Drug Resistance in Childhood Acute Lymphoblastic Leukemia by Regulating Wnt/β-Catenin Signaling Pathway].
    Huang HM; Wei YJ; Wang D; Wen XM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Apr; 30(2):418-424. PubMed ID: 35395973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of heme oxygenase-1 in microenvironment mediates vincristine resistance of B-cell acute lymphoblastic leukemia by promoting vascular endothelial growth factor secretion.
    Yu K; Wang J; Lu T; Ma D; Wei D; Guo Y; Cheng B; Wang W; Fang Q
    J Cell Biochem; 2019 Oct; 120(10):17791-17810. PubMed ID: 31264739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pitavastatin induces apoptosis in oral squamous cell carcinoma through activation of FOXO3a.
    Lee N; Tilija Pun N; Jang WJ; Bae JW; Jeong CH
    J Cell Mol Med; 2020 Jun; 24(12):7055-7066. PubMed ID: 32406610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of cIAP-1 by novel antitubulin agents when combined with bryostatin 1 results in increased apoptosis in the human early pre-B acute lymphoblastic leukemia cell line Reh.
    Wall NR; Mohammad RM; Nabha SM; Pettit GR; Al-Katib AM
    Biochem Biophys Res Commun; 1999 Dec; 266(1):76-80. PubMed ID: 10581168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo.
    Yang J; Ikezoe T; Nishioka C; Tasaka T; Taniguchi A; Kuwayama Y; Komatsu N; Bandobashi K; Togitani K; Koeffler HP; Taguchi H; Yokoyama A
    Blood; 2007 Sep; 110(6):2034-40. PubMed ID: 17495131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A role for altered microtubule polymer levels in vincristine resistance of childhood acute lymphoblastic leukemia xenografts.
    Ong V; Liem NL; Schmid MA; Verrills NM; Papa RA; Marshall GM; Mackenzie KL; Kavallaris M; Lock RB
    J Pharmacol Exp Ther; 2008 Feb; 324(2):434-42. PubMed ID: 17986648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of c-Myc using 10058-F4 exerts caspase-3-dependent apoptosis and intensifies the antileukemic effect of vincristine in pre-B acute lymphoblastic leukemia cells.
    Sheikh-Zeineddini N; Bashash D; Safaroghli-Azar A; Riyahi N; Shabestari RM; Janzamin E; Safa M
    J Cell Biochem; 2019 Aug; 120(8):14004-14016. PubMed ID: 30957273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic Anticancer Effects of Gemcitabine with Pitavastatin on Pancreatic Cancer Cell Line MIA PaCa-2 in vitro and in vivo.
    Chen YH; Chen YC; Lin CC; Hsieh YP; Hsu CS; Hsieh MC
    Cancer Manag Res; 2020; 12():4645-4665. PubMed ID: 32606957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-Faceted Effects of ST6Gal1 Expression on Precursor B-Lineage Acute Lymphoblastic Leukemia.
    Zhang M; Qi T; Yang L; Kolarich D; Heisterkamp N
    Front Oncol; 2022; 12():828041. PubMed ID: 35371997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving chemotherapeutic efficiency in acute myeloid leukemia treatments by chemically synthesized peptide interfering with CXCR4/CXCL12 axis.
    Li X; Guo H; Duan H; Yang Y; Meng J; Liu J; Wang C; Xu H
    Sci Rep; 2015 Nov; 5():16228. PubMed ID: 26538086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dye-mediated photolysis is capable of eliminating drug-resistant (MDR+) tumor cells.
    Lemoli RM; Igarashi T; Knizewski M; Acaba L; Richter A; Jain A; Mitchell D; Levy J; Gulati SC
    Blood; 1993 Feb; 81(3):793-800. PubMed ID: 8427970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells.
    Tu HJ; Lin YJ; Chao MW; Sung TY; Wu YW; Chen YY; Lin MH; Liou JP; Pan SL; Yang CR
    Clin Epigenetics; 2018 Dec; 10(1):162. PubMed ID: 30594243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Galectin-1 and Galectin-3 in B-Cell Precursor Acute Lymphoblastic Leukemia.
    Fei F; Zhang M; Tarighat SS; Joo EJ; Yang L; Heisterkamp N
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pitavastatin and metformin synergistically activate apoptosis and autophagy in pancreatic cancer cells.
    Chen YH; Huang YC; Yang SF; Yen HH; Tsai HD; Hsieh MC; Hsiao YH
    Environ Toxicol; 2021 Aug; 36(8):1491-1503. PubMed ID: 33886150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bax:Bcl-2 ratio modulation by bryostatin 1 and novel antitubulin agents is important for susceptibility to drug induced apoptosis in the human early pre-B acute lymphoblastic leukemia cell line, Reh.
    Wall NR; Mohammad RM; Al-Katib AM
    Leuk Res; 1999 Oct; 23(10):881-8. PubMed ID: 10573132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shp2 activation in bone marrow microenvironment mediates the drug resistance of B-cell acute lymphoblastic leukemia through enhancing the role of VCAM-1/VLA-4.
    Yu K; Yin Y; Ma D; Lu T; Wei D; Xiong J; Zhou Z; Zhang T; Zhang S; Fang Q; Wang J
    Int Immunopharmacol; 2020 Mar; 80():106008. PubMed ID: 31978797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.